Sokolski Kenneth N, Denson Thomas F, Lee Robert T, Reist Christopher
Long Beach VA Health Care System, Mental Health Care Group, Long Beach, CA, USA.
Mil Med. 2003 Jun;168(6):486-9.
To assess the effects of adjunctive quetiapine for treatment of refractory symptoms of combat-related post-traumatic stress disorder (PTSD), charts of Vietnam veterans with war-connected PTSD who had been prescribed quetiapine were reviewed. Only patients with symptoms that had not responded to adequate therapy with two or more psychotropic medications prior to quetiapine treatment were analyzed. Addition of quetiapine to ongoing therapy resulted in further symptomatic improvements in DSM-IV PTSD criterion B (re-experiencing) for 35%, criterion C (avoidance/numbing) for 28%, and criterion D (arousal) for 65% of study subjects. Low doses of quetiapine (mean = 155 +/- 130 mg) were associated with minimal side effects. These results, although retrospective, suggest that augmentative quetiapine may benefit some refractory symptoms of PTSD in combat veterans.
为评估喹硫平辅助治疗与战斗相关的创伤后应激障碍（PTSD）难治性症状的效果，我们回顾了曾开具喹硫平处方的患有与战争相关PTSD的越南退伍军人的病历。仅分析了在喹硫平治疗前使用两种或更多种精神药物进行充分治疗但症状未得到缓解的患者。在持续治疗中加用喹硫平后，35%的研究对象在DSM-IV PTSD标准B（再体验）、28%在标准C（回避/麻木）以及65%在标准D（觉醒）方面症状进一步改善。低剂量喹硫平（平均 = 155 +/- 130毫克）的副作用最小。这些结果虽然是回顾性的，但表明增效喹硫平可能对战斗退伍军人PTSD的一些难治性症状有益。
